Lee, H.J.;                     Shin, S.;                     Kang, J.;                     Han, K.-C.;                     Kim, Y.H.;                     Bae, J.-W.;                     Park, K.H.    
        HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line. Cancers 2020, 12, 2630.
    https://doi.org/10.3390/cancers12092630
    AMA Style
    
                                Lee HJ,                                 Shin S,                                 Kang J,                                 Han K-C,                                 Kim YH,                                 Bae J-W,                                 Park KH.        
                HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line. Cancers. 2020; 12(9):2630.
        https://doi.org/10.3390/cancers12092630
    
    Chicago/Turabian Style
    
                                Lee, Hye Jin,                                 Seungho Shin,                                 Jinho Kang,                                 Ki-Cheol Han,                                 Yeul Hong Kim,                                 Jeoung-Won Bae,                                 and Kyong Hwa Park.        
                2020. "HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line" Cancers 12, no. 9: 2630.
        https://doi.org/10.3390/cancers12092630
    
    APA Style
    
                                Lee, H. J.,                                 Shin, S.,                                 Kang, J.,                                 Han, K.-C.,                                 Kim, Y. H.,                                 Bae, J.-W.,                                 & Park, K. H.        
        
        (2020). HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line. Cancers, 12(9), 2630.
        https://doi.org/10.3390/cancers12092630